Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
Lists including Rob
Investments
Work Experience
Managing Partner
2017
- Life sciences venture capital firm focused on North American and European biotech - Built team and operations, and co-led investment, fundraising, and LP management activities in two biotech venture capital funds totaling $689 million under management Key investments include: - Arcutis Therapeutics (NASDAQ: ARQT), Evommune, Inc, Exscientia, Inc (acquired by Recursion), Gracell Therapeutics (acquired by Astra Zeneca), Karuna Therapeutics (acquired by BMS), Oculis Therapeutics (NASDAQ: OCS), Vaxcyte Therapeutics (NASDAQ: PCVX)
Executive Committee Member
2022
Oversight of public investment, VC fund investments, and Pivotal bioVenture Partners investment activities
2020
Board Member
2020
2021
Board Member
2021
2019
Board Member
2019
2017 - 2023
Board Member
2017 - 2023
2017 - 2021
Board Member
2017 - 2021
2006 - 2017
Managing Director and Partner
2009 - 2017
Life sciences venture capital firm focused on North American and European biotech Led or co-led 12 investments as a Partner at the firm with top-tier returns and low loss-rate Key investments include: - Civitas Therapeutics (acquired by Acorda), Dermira (acquired by Lilly), Hyperion Therapeutics (acquired by Horizon Pharma), Madrigal Pharmaceuticals (NASDAQ: MDGL), Merus Therapeutics (NASDAQ: MRUS), NextWave Pharmaceuticals (acquired by Pfizer), Protez (acquired by Novartis), Vtesse (acquired by Sucampo), and Zymogenetics (acquired by BMS)
Principal
2006 - 2009
2015 - 2017
Board Member
2015 - 2017
Rare disease company acquired by Sucampo Therapeutics
2013 - 2014
Board Member
2013 - 2014
2010 - 2014
Board Observer
2010 - 2014
Dermatology drug development company acquired by Lilly, Inc.